leadf
logo-loader
viewNetscientific PLC

NetScientific investee company receives second funding tranche from Chinese pharma giant

Glycotest Inc has received US$3mln, which help fund the commercialisation of its liver cancer diagnostic

Netscientific PLC -

NetScientific PLC (LON:NSCI) said investee company Glycotest Inc has received a second US$3mln tranche of its US$10mln Series A fundraising round with China’s Fosun Pharmaceutical.

The cash injection will allow Glycotest to advance towards commercial launch its algorithm-driven test for hepatocellular carcinoma, a form of liver cancer.

“We are proud to be supporters of Glycotest who we believe has the strong potential to deliver value for our shareholders,” said NetScientific chief executive Ian Postlethwaite.

Quick facts: Netscientific PLC

Price: 62 GBX

AIM:NSCI
Market: AIM
Market Cap: £9.25 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Netscientific PLC named herein, including the promotion by the Company of Netscientific PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Investor Update: ANGLE reports positive data from Parsortix FDA clinical study

Top stories from the Proactive Investors UK newsroom: ANGLE PLC (LON:AGL) has received positive results from its Parsortix FDA clinical study for metastatic breast cancer. The 400-subject clinical study will support an application for Class II regulatory clearance for Parsortix in the...

on 31/5/19

2 min read